88 related articles for article (PubMed ID: 16203769)
1. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors.
Izumi M; Oyanagi J; Sawa K; Fukui M; Ogawa K; Matsumoto Y; Tani Y; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Ohsawa M; Yamamoto N; Koh Y; Kawaguchi T
Sci Rep; 2021 Mar; 11(1):5680. PubMed ID: 33707471
[TBL] [Abstract][Full Text] [Related]
3. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma.
Uysal M; Beypinar I; Araz M
J Cancer Res Ther; 2024 Jan; ():. PubMed ID: 38261436
[TBL] [Abstract][Full Text] [Related]
4. EGFR mutations and lung cancer.
da Cunha Santos G; Shepherd FA; Tsao MS
Annu Rev Pathol; 2011; 6():49-69. PubMed ID: 20887192
[TBL] [Abstract][Full Text] [Related]
5. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR; Yang P; Cassivi SD; Schild SE; Adjei AA
Mayo Clin Proc; 2008 May; 83(5):584-94. PubMed ID: 18452692
[TBL] [Abstract][Full Text] [Related]
6. Role of intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer.
Yamazaki M; Yagi T; Tominaga M; Minato K; Ishikawa H
Br J Radiol; 2022 Dec; 95(1140):20220374. PubMed ID: 36115683
[TBL] [Abstract][Full Text] [Related]
7. Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review.
Huang Y; Cho HJ; Stranger BE; Huang RS
Transl Lung Cancer Res; 2022 May; 11(5):920-934. PubMed ID: 35693273
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.
Cai L; Wang J; Yan J; Zeng J; Zhu L; Liang J; Pan C; Huang X; Jin J; Xu Y; Wang F; Shao Y; Xu Q; Xia G; Xing M; Xu X; Jiang Y
Front Oncol; 2020; 10():603671. PubMed ID: 33505917
[TBL] [Abstract][Full Text] [Related]
9.
Calibasi-Kocal G; Amirfallah A; Sever T; Umit Unal O; Gurel D; Oztop I; Ellidokuz H; Basbinar Y
Biomed Rep; 2020 Aug; 13(2):2. PubMed ID: 32509305
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.
Martinez-Marti A; Navarro A; Felip E
Transl Lung Cancer Res; 2019 Nov; 8(Suppl 3):S235-S246. PubMed ID: 31857948
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report from Iran.
Mohammadzadeh S; Jowkar Z; Mirzai M; Geramizadeh B
Iran J Pathol; 2019; 14(1):1-7. PubMed ID: 31531095
[TBL] [Abstract][Full Text] [Related]
12. Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations.
Miyauchi E; Matsuda T; Kiyotani K; Low SK; Hsu YW; Tsukita Y; Ichinose M; Sakurada A; Okada Y; Saito R; Nakamura Y
Cancer Sci; 2019 Mar; 110(3):867-874. PubMed ID: 30582659
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.
Tung JN; Lin PL; Wang YC; Wu DW; Chen CY; Lee H
Oncotarget; 2018 Jan; 9(4):4637-4646. PubMed ID: 29435131
[TBL] [Abstract][Full Text] [Related]
14. Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.
Kimura K; Takayanagi R; Fukushima T; Yamada Y
Med Oncol; 2017 Sep; 34(10):178. PubMed ID: 28887613
[TBL] [Abstract][Full Text] [Related]
15. The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Cha YK; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Choi YL; Lee KS
J Thorac Dis; 2016 Nov; 8(11):3175-3186. PubMed ID: 28066597
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancer.
Lin YK; Hsu HL; Lin WC; Chang JH; Chang YC; Chang CL; Yuan KS; Wu ATH; Wu SY
Oncotarget; 2017 May; 8(21):35280-35288. PubMed ID: 27835914
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables.
Kasana BA; Dar WR; Aziz SA; Lone AR; Sofi NU; Dar IA; Latief M; Arshad F; Hussain M; Hussain M
Indian J Med Paediatr Oncol; 2016; 37(3):189-95. PubMed ID: 27688613
[TBL] [Abstract][Full Text] [Related]
18. Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer.
Li D; Du XL; Ren Y; Liu P; Li S; Yang J; Lv M; Chen L; Wang X; Li E; Yang J; Yi M
PLoS One; 2016; 11(5):e0156617. PubMed ID: 27244238
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
Midha A; Dearden S; McCormack R
Am J Cancer Res; 2015; 5(9):2892-911. PubMed ID: 26609494
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
